KRAS and leukemia: Activation of alternative pathways, such as KRAS/RAC1/ROS/NLRP3, in leukemia cells [70, 71] or non-hematopoietic cells [72] may also lead to the production of pro-inflammatory IL-1β that promotes leukemia cell proliferation in an autocrine fashion.